No 02 2025

Abera Bioscience has announces that CEPI (Coalition for Epidemic Preparedness Innovations) has decided to extend the ongoing project supporting the development of Abera’s BERA vaccine platform and the company’s innovative influenza vaccine candidate. 

Aplagon has announced the close of a EUR 4.8 million (approx. USD 5.6 million) financing round to support its expansion into a new Phase 2 clinical programme in arteriovenous fistula (AVF) maturation failure in end stage kidney disease.

NLS asked Azza Chammem, Associate Director at Scope Ratings, a European credit rating agency, how the current conflict in the Middle East has affected the life science industry and what the future effects might be.

Immunovia has announced new performance data for PancreaSure in support of its upcoming Medicare coverage application.

By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization, the company states.

SynAct Pharma has reported that resomelagon in combination with methotrexate showed promising clinical effects on par with previous findings with ACR20 reaching 76,4% in the most effective dose compared to 60,8% in the placebo treated control group reaching statistical significance in the subset of patients entering the study with ACR/EULAR class II-III disease.

Johnny Mogensen most recently comes from a position as Denmark’s research and innovation attaché in Boston, USA. He has held several positions in the Danish Agency for Higher Education and Science and has also previously been posted to Brussels as an adviser to Denmark’s EU delegation and as a national expert to the European Commission.